Group One Trading
BCAX

Group One Trading’s Bicara Therapeutics BCAX Stock Holding History

Group One Trading’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$1.68K – 9003
2025
Q4 		$1.68K Hold
100
– – ﹤0.01% 7604
2025
Q3 		$1.58K Buy
+100
New +$1.12K ﹤0.01% 7964

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Group One Trading's BCAX Position: Q1 2026 in Review

Group One Trading reduced its Bicara Therapeutics (BCAX) stake by 92% in Q1 2026, selling an estimated $269K and leaving 1,306 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #5784.

Group One Trading first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. The position peaked at $285K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Group One Trading held 1,306 shares of Bicara Therapeutics worth $26K as of Q1 2026.
  • Group One Trading sold 15,608 Bicara Therapeutics shares in Q1 2026, an estimated $269K.
  • Bicara Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5784 holding.
  • Group One Trading first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Group One Trading's Bicara Therapeutics position peaked at $285K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.